Viking Therapeutics Advances in Crowded Weight-Loss Drug Arena

Viking Therapeutics completes enrollment for two key Phase 3 obesity/diabetes trials for VK2735, advancing toward a 2027 regulatory filing amid a shifting competitive landscape.

Viking Therapeutics has achieved a pivotal milestone for its lead drug candidate, moving closer to a potential regulatory submission. The biopharmaceutical company has completed patient enrollment for a crucial late-stage trial, setting the stage for its entry into the highly competitive metabolic disease market.

Late-Stage Trials Set the Stage

The company has finalized recruitment for its Phase 3 clinical study, known as VANQUISH-2. This trial involves approximately 1,000 adult participants who are living with obesity or overweight alongside Type 2 diabetes. With a parallel Phase 3 study, VANQUISH-1, also fully enrolled, Viking now has the foundation to thoroughly evaluate its dual GLP-1/GIP receptor agonist, VK2735.

Expectations for the upcoming trial results are anchored in prior data. In an earlier Phase 2 study (VENTURE), subjects receiving weekly doses of VK2735 achieved an average weight reduction of up to 14.7% over a 13-week period. Market observers are using these figures as a benchmark for the ongoing Phase 3 program.

Navigating a Rapidly Evolving Competitive Landscape

These developmental strides come amid significant upheaval in the metabolic therapy sector. The competitive intensity was recently heightened by industry giant Eli Lilly, which entered a collaboration worth up to $2.75 billion with Insilico Medicine. This partnership aims to leverage artificial intelligence to dramatically accelerate the discovery of new GLP-1-based treatments.

Concurrently, global pricing dynamics are shifting. Following the expiration of Novo Nordisk's patent for its semaglutide compound in India this month, dozens of local manufacturers are introducing lower-cost generic versions. This trend highlights the substantial global demand for these therapies but also introduces future pricing pressures for new market entrants.

A Clear Path Toward Regulatory Submission

Viking Therapeutics is targeting 2027 for the formal submission of its application for marketing approval. Investor attention is now firmly fixed on the forthcoming data readouts from the two fully enrolled Phase 3 trials. A positive outcome from these studies is the essential prerequisite for establishing VK2735 as a standalone alternative to the currently dominant players in the obesity and diabetes treatment space.